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Abstract
Recent advances have permitted successful therapeutic targeting of the immune system in head 
and neck squamous cell carcinoma (HNSCC). These new immunotherapeutic targets and agents 
are being rapidly adopted by the oncologic community and hold considerable promise. The 
National Cancer Institute sponsored a Clinical Trials Planning Meeting to address the issue of how 
to further investigate the use of immunotherapy in patients with HNSCC. The goals of the meeting 
were to consider phase 2 or 3 trial designs primarily in 3 different patient populations: those with 
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A particular note is made of the enduring contributions of the late Holbrook Kohrt, MD, PhD, a visionary translational 
immunotherapist, who thoughtfully contributed to this Clinical Trials Planning Meeting from his extensive experience in the field.
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previously untreated, human papillomavirus-initiated oropharyngeal cancers; those with 
previously untreated, human papillomavirus-negative HNSCC; and those with recurrent/metastatic 
HNSCC. In addition, a separate committee was formed to develop integrative biomarkers for the 
clinical trials. The meeting started with an overview of key immune components and principles 
related to HNSCC, including immunosurveillance and immune escape. Four clinical trial concepts 
were developed at the meeting integrating different immunotherapies with existing standards of 
care. These designs were presented for implementation by the head and neck committees of the 
National Cancer Institute-funded National Clinical Trials Network. This article summarizes the 
proceedings of this Clinical Trials Planning Meeting, the purpose of which was to facilitate the 
rigorous development and design of randomized phase 2 and 3 immunotherapeutic trials in 
patients with HNSCC. Although reviews usually are published immediately after the meeting is 
held, this report is unique because there are now tangible clinical trial designs that have been 
funded and put into practice and the studies are being activated to accrual.
Keywords
checkpoint inhibitors; clinical trials; head and neck cancer; human papillomavirus; 
immunotherapy
INTRODUCTION
The objective of cancer immunotherapy is to reactivate the immune system to target 
malignant cells, and it has been demonstrating recent clinical efficacy in many cancer types.1 
Derangements in the immune system or alterations in the transformed cells may allow 
immune escape, which then enables the cancer to manifest. Immunomodulatory therapies 
that overcome immune suppressive signals in patients with Head and Neck Squamous Cell 
Carcinoma (HNSCC) have therapeutic promise.2 The recent clinical efficacy of US Food 
and Drug Administration (FDA)-approved monoclonal antibodies (MoAbs) targeting 
immune checkpoint receptors, including anticytotoxic T-lymphocyte antigen 4 (anti-
CTLA-4) and anti-programmed cell death protein 1 (anti-PD-1), provided further potential 
for patient benefit as positive clinical data emerge. This led to the approval by the National 
Cancer Institute (NCI) of a proposal to convene a group of experts focused on developing 
immunotherapies rationally and integrating this novel modality into conventional 
radiotherapy (RT), chemotherapy, and surgical oncologic therapies.
The meeting (which was held November 9–10, 2014 at the NCI Clinical Center in Bethesda, 
MD) began with a series of scientific overview presentations focused on the mechanisms of 
immune escape in HNSCC, as well as different targets, classes of agents, and information 
gained from immunotherapy in other diseases such as melanoma and lung and renal cell 
carcinoma. The concept was established that to establish effective immunotherapies, 
understanding the different pathways of tumor immune evasion is necessary. The profound 
although apparently selective immunosuppression in HNSCC ranges from lymphopenia, to 
altered secretion of normal cytokines and inflammatory signaling pathways, to aberrant 
skewing of cellular immunity, abetted by suppressive populations such as CD4-positive 
regulatory T cells (Treg), macrophages, and myeloid-derived suppressor cells (MDSCs).
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MoAb-Based Immunotherapy for HNSCC
Today, the most widely used form of cancer immunotherapy is MoAb therapy,3 including 
tumor antigen (TA)-targeted MoAbs, cytokine-targeted MoAbs, tumor necrosis factor 
receptor (TNFR) family costimulatory targeted MoAbs, and immune checkpoint-targeted 
MoAbs (Table 1). To our knowledge, the best studied FDA-approved agent for HNSCC is 
cetuximab, a mouse-human chimeric immunoglobulin (Ig) G1 antiepidermal growth factor 
receptor (EGFR) MoAb.4,5 Anti-EGFR MoAbs can mediate antigen-specific immune 
responses through direct killing via natural killer (NK) cell or monocytes lysis or tumor 
phagocytosis and subsequent antigen processing. In addition to extensive clinical and 
correlative immune response data using cetuximab, MEHD7945A, an antihuman epidermal 
growth factor receptor 3 (HER3)/EGFR human MoAb targeting HER3 and EGFR, is 
currently being tested in a phase 1/2 clinical trials for HNSCC (ClinicalTrials.gov identifiers 
NCT01577173 and NCT01911598). Enhancing the secondary immune response to TA-
targeted MoAbs by combination with other immune-targeted therapies is a particularly 
appealing approach for patients with HNSCC, given that cetuximab is a standard, FDA-
approved agent in those with locally advanced or recurrent/metastatic (R/M) disease.
Immune checkpoints and costimulatory receptors in HNSCC—Costimulatory 
molecules modify T-cell activation, and the duration and extent of immune responses is 
regulated by coinhibitory pathways (called “immune checkpoints”) that prevent excessive 
autoimmunity. Immune checkpoints can be manipulated as a mechanism of tumor immune 
evasion.6 Examples include CTLA-4 and its ligands CD80 and CD86 and PD-1 and its 
ligands PD-L1 and PD-L2. Blocking anti-CTLA-4 MoAb therapy results in the rejection of 
syngeneic murine cancers.7 An anti-CTLA-4 MoAb, ipilimumab, demonstrated clinical 
benefit and was approved by the FDA in 2011 for patients with metastatic melanoma.8 
Tremelimumab also targets CTLA-4 and currently is under investigation in patients with 
HNSCC. More recently, anti-PD-1 or PD-L1 MoAbs have demonstrated clinical efficacy, 
either alone9–11 or in combination with ipilimumab,12 including in patients with 
HNSCC.13,14
Evasion of antitumor immunity by HNSCC occurs by high tumor expression of PD-L1 
and/or tumor immune infiltration by PD-1-positive T lymphocytes.15 PD-L1 is expressed in 
50% to 60% of HNSCC,16 and tumor infiltration by PD-1-positive regulatory T cells (Treg) 
may be more common for patients with human papillomavirus (HPV)-positive compared 
with HPV-negative HNSCC.17 Indeed, membrane and/or intracytoplasmic PD-L1 expression 
is common in both types of HNSCC.18 Importantly, these studies also demonstrated that 
expression of PD-L1 can be induced by interferon gamma (IFN-γ), suggesting that the 
tumor microenvironment (TME) dictates tumor expression of PD-L1 and that measurement 
of PD-L1 at a single time point or location may not accurately reflect the natural history of 
its expression.19 Badoual et al reported tumor infiltration by PD-1-positive, CD8-positive, 
and PD-1-positive and CD4-positive lymphocytes was more common among patients with 
HPV-positive than HPV-negative HNSCC. In 33 of 64 cases of HNSCC (52%), high levels 
of PD-L1 expression were observed, but there was no association between PD-L1 expression 
and tumor HPV status.17 A higher expression of immune checkpoint receptors (CTLA-4 and 
PD-1) in intratumoral Treg cells compared with on matched peripheral blood samples has 
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been observed among patients with HNSCC.20 These data strongly support a role for PD-1 
inhibition in the treatment of patients with HNSCC. Seiwert et al recently reported 
promising preliminary efficacy associated with the anti-PD-1 MoAb pembrolizumab in a 
large (>130 patients) phase 1b cohort with refractory, R/M HNSCC, as measured by 
response rate and overall survival (OS).14 In a CheckMate 141 study, a randomized phase 3 
trial of nivolumab versus single-agent chemotherapy, an OS benefit was observed,21 with a 
30% improvement in OS and a doubling of patients alive at 1 year, indicating that FDA 
approval for this agent is imminent. Pembrolizumab was approved by the FDA in August 
2016 for the treatment of HNSCC. Anti-PD-1 MoAbs also are being tested in various novel 
combinations in the phase 1 setting, such as nivolumab plus an agonistic anti-CD137 MoAb 
(urelumab; ClinicalTrials.gov identifier NCT02253992) and nivolumab plus an anti-
lymphocyte-activation protein 3 (LAG-3) MoAb (ClinicalTrials.gov identifier 
NCT01968109), as well as cetuximab plus urelumab (ClinicalTrials.gov identifier 
NCT02110082).
Other checkpoint receptors (Table 2) such as LAG-3 or the killer-cell immunoglobulin-like 
receptors, which interact with major histocompatibility complex (MHC) molecules to 
regulate immune responses, currently are being investigated in combination with anti-PD-1. 
Ongoing pharmaceutical-sponsored trials include the investigation of an anti-killer-cell 
immunoglobulin-like receptor MoAb in combination with the anti-CTLA-4 MoAb 
ipilimumab (ClinicalTrials.gov identifier NCT01750580) or the anti-PD-1 MoAb nivolumab 
(ClinicalTrials.gov identifier NCT01714739).
In addition to blocking negative regulatory receptors on effector lymphocytes, another 
strategy has emerged to enhance and trigger positive, costimulatory signals using agonistic 
MoAbs and small molecules. To our knowledge to date, the investigation of TNFR-targeting 
MoAbs in clinical trials for HNSCC currently is in phase 1. Because of the important 
costimulatory pathways for immune cell activation, substances such as CP-870,893 (Pfizer), 
an IgG2 CD40 agonist; OX40 MoAb (AstraZeneca/Medimmune), an IgG2 OX40 agonist; or 
urelumab (Bristol-Myers Squibb), an IgG4 CD137 agonist, have been investigated with 
cetuximab or with nivolumab in clinical trials.22 Toll-like receptor agonists induce the 
maturation and cross-priming of dendritic cells (DCs), and have been shown to induce NK 
cell-dependent lysis of tumor cells in combination with TA-targeted MoAbs such as the anti-
EGFR MoAb cetuximab.23 The toll-like receptor 8 -agonist motolimod currently is under 
investigation in combination with cetuximab-based therapy in patients with HNSCC 
(ClinicalTrials.gov NCT02124850 and NCT01334177).
Integration of Immunotherapy into Clinically Defined Patient Groups
The NCI-funded Clinical Trials Planning Meeting facilitated the rational design of 
combinations of immunotherapies for phase 2 and 3 randomized trials in patients with 
HNSCC. The meeting was organized around 4 breakout groups. Three groups were focused 
on specific biologic subsets of HNSCC: HPV-positive, previously untreated, locally 
advanced (PULA) disease; HPV-negative PULA disease; and R/M HNSCC. A fourth group 
of scientists focused on correlative tissue and imaging biomarkers. After developing 
harmonized recommendations for biomarker and imaging correlatives, this fourth group’s 
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proposed correlative studies and assays were integrated into the discussions and trial designs 
emanating from the 3 therapeutic cohort groups.
Recurrent/metastatic HNSCC—Patients with R/M HNSCC have a particularly poor 
prognosis, with a median OS of approximately 10 months. Akin to what is observed in the 
setting of primary disease, patients with HPV-positive R/M tumors enjoy improved 
outcomes, with a 2-year OS rate of approximately 55% versus 28% for their HPV-negative 
counterparts.24 For nearly 3 decades, the cornerstone of first-line palliative systemic therapy 
has been cisplatin,25 frequently combined with 5-fluorouracil or a taxane due to increased 
response rates (albeit with no conclusive evidence of superior OS compared with cisplatin 
monotherapy).26 In 2006, cetuximab became the first FDA-approved, TA-targeted MoAb for 
patients with HNSCC. When combined with platinum and 5-fluorouracil, cetuximab 
increased both progression-free survival and OS in patients with R/M disease (the so-called 
“EXTREME” regimen).27 Cetuximab also is indicated as monotherapy in patients with R/ 
M, platinum-refractory HNSCC.28 Unfortunately, these treatments generally are not curative 
and to the best of our knowledge no established therapies exist for the cetuximab-refractory 
population, which is an area of profound unmet need.
In response to this therapeutic void, there has been a proliferation of clinical trials testing 
immunotherapeutic MoAbs in patients with R/M disease (Table 2). For example, a phase 1b 
clinical trial investigated the anti-PD-1 MoAb pembrolizumab (MK-3475; Merck) and 
yielded response rates (partial response/complete response) of approximately 20%. 
Importantly, and contrary to existing data with standard chemotherapeutics, response rates 
were found to be similar in both HPV-positive and HPV-negative cohorts. These early 
efficacy data were substantiated in the recent phase 3 trial, CheckMate 141, which compared 
single-agent nivolumab with investigator’s choice single-agent therapy. This trial closed 
early when an OS benefit was shown (360 patients) (ClinicalTrials.gov identifier 
NCT02105636), and the results will be reported in the near future.21
Importantly, these promising results are not limited to anti-PD-1, as anti-PD-L1 also has 
demonstrated comparable efficacy in a phase 1 trial. The success of this initial study 
prompted the design of a phase 3 trial evaluating MEDI4736 alone or in combination with 
the anti-CTLA-4 MoAb tremelimumab compared with standard of care, second-line agents 
(720 patients) (ClinicalTrials.gov identifier NCT02369874). Stratification by PD-L1 
expression status is planned.
Based on the positive outcomes found to be associated with the use of checkpoint inhibition 
after first-line failure, a recently initiated phase 3 trial will now move PD-1 targeting forward 
into the first-line setting for patients with R/M disease. Specifically, this trial will compare 
the anti-PD-1 MoAb pembrolizumab alone or in combination with platinum/5-fluorouracil 
versus the EXTREME regimen (600 patients) (ClinicalTrials.gov identifier NCT02358031). 
Despite the excitement generated by the evaluation of checkpoint inhibition as first-line 
therapy in the R/M setting, the uncomfortable reality is that a large number of these treated 
patients will likely continue to die of their disease. Indeed, it was this reality that prompted 
the formation of the R/M disease working group, which was charged with the development 
of clinical trials to meet the needs of patients whose disease is refractory to existing therapy.
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Although many trials were proposed for development, the clinical trial eventually adopted 
by the recurrent metastatic working group was the brainchild of the late Dr. Holbrook Kohrt. 
This trial design was premised on 2 fundamental considerations: first, that defined 
cosignaling pathways can be induced on Fc γ receptor (FcγR)-bearing immune effector 
cells through FcγR engagement by the aggregated Fc fragments of immobilized 
antibodies29; and second, that blockade of select immunologic checkpoints (eg, PD-1/PD-
L115,30 in combination with the stimulation of defined cosignaling molecules (eg, CD137 
[4-1BB]) have synergistic antitumor activity. His laboratory and that of one of the coauthors 
(R.L.F.) have demonstrated that engagement of CD16 on the surface of NK cells induced 
high levels of CD137 expression.31,32 Subsequent studies demonstrated that CD137 could be 
induced on NK cells by the Fc fragments of antibodies bound to the tumor cell surface and 
that engagement of CD137 on these NK cells33,34 or by DC35 by agonistic antibodies could 
potentiate their antitumor activity.32
Based on these data, the working group proposed a prospective randomized clinical trial 
design with 3 arms. In this schema, all groups would receive cetuximab “induction” on day 
1, followed by additional doses on days 8 and 15. Importantly, the purpose of cetuximab 
administration in this setting was not simply to mediate killing of EGFR-expressing tumors 
but also to induce CD137 expression on the surface of infiltrating NK cells. On study day 2, 
patients in group 1 would receive an agonistic MoAb against CD137, patients in group 2 
would receive anti-PD-1 or anti-PD-L1, and patients in group 3 would receive a combination 
of anti-CD137/PD-1 or PD-L1. Each cycle was designed to last 21 days and response to 
treatment would be assessed at the end of 12 cycles. The 2 primary endpoints were safety 
and 6-month progression-free survival. Successful completion of the study would enable 
determination of: 1) the ability of cetuximab to induce CD137 on circulating NK cells in 
patients with HNSCC; and 2) the ability of anti-CD137/ PD-1 or PD-L1 to improve survival 
in comparison with either agent alone. A limitation of the design might be the inability to 
include a cetuximabonly cohort, based on feasibility considerations, as well the lack of 
toxicity or efficacy data for combinations with urelumab (agonistic anti-CD137).
Role of immunity in response to chemoradiotherapy—Cytotoxic cancer therapies 
alone are aimed at tumor eradication through the direct killing of cancer cells. However, full 
and sustained clinical remission is elusive for many patients receiving standard-of-care 
treatments. Striking clinical observations in recent years have indicated that patients 
harboring certain malignancies achieved higher clinical benefit with immunotherapy if 
previously treated with certain anticancer therapies. These observations are now supported 
by accumulating evidence demonstrating that conventional and emerging anticancer 
therapies modulate the tumor to induce a more immunostimulatory milieu.36,37
Immunogenic cell death and immunogenic modulation by chemoradiotherapy
—Cancer therapeutic regimens trigger cancer cell death while stimulating endogenous 
immune responses against the tumor, termed “immunogenic cell death.”37,38 The cardinal 
signs of immunogenic cell death are 1) calreticulin exposure on the surface of dying cells; 2) 
the release of HMGB1; and 3) the release of ATP, which acts on DCs to facilitate the 
presentation of TAs to the immune system. Tumor cells that survive therapy have been 
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shown to alter their biology to render them more sensitive to immune-mediated killing, 
termed “immunogenic modulation.”36,39 Immunogenic modulation encompasses a spectrum 
of molecular alterations in the biology of the cancer cell that independently or collectively 
make the tumor more amenable to cytotoxic T-lymphocyte (CTL)– mediated destruction. 
These include: 1) downregulation of antiapoptotic/survival genes; 2) modulation of antigen-
processing machinery components; and 3) calreticulin translocation to the cell surface of the 
tumor. One can envision that these immunogenic consequences of anticancer therapy, 
ranging from immunogenic cell death to immunogenic modulation, can be harnessed to 
achieve synergy with immunotherapy regimens, therefore maximizing the clinical benefit for 
patients with HNSCC receiving combination therapy.
If immunotherapies are to be used early in the disease process, they would most likely need 
to be used in combination with chemotherapeutic agents. Although counterintuitive, it has 
recently been shown that immunotherapy may not only be compatible with chemotherapy, 
but also actually may be synergistic. Various chemotherapy agents have been shown to 
induce immunogenic modulation in tumors of diverse origin by upregulating immune-
relevant proteins on the surface of cancer cells, including TAs, calreticulin, adhesion 
molecules such as intercellular adhesion molecule 1 (ICAM-1), and MHC class I proteins. 
These phenotypic changes translated into increased murine and/or human tumor sensitivity 
to CTL-mediated lysis in vitro after exposure to sublethal doses of chemotherapy with 
cisplatin,40 taxanes,41 or cisplatin plus vinorelbine.42 These preclinical findings and others 
have translated into various hypothesis-generating clinical trials. Several points are 
important when considering the use of chemotherapy with immunotherapy: 1) the combined 
use of immunotherapy and chemotherapy early in the disease process should not be 
confused with the use of immunotherapy after multiple regimens of different 
chemotherapeutic agents in the advanced disease setting, in which the immune system 
would most likely be impaired; 2) not all chemotherapeutic agents will be synergistic with 
immunotherapy; and 3) the dose and scheduling of immunotherapy when used with 
chemotherapy may be extremely important, and after immune function may guide trial 
optimization.
Checkpoint inhibitors and radiotherapy—Radiotherapy (RT) can induce a continuum 
of immunogenic alterations in dying and/or surviving tumor cells. Lethal irradiation has 
been reported to induce immunogenic cell death. Although immune responses in patients 
with cancer undergoing RT alone are often weak and rarely translate into protective 
immunity, the immunogenic effects of RT can be exploited to promote synergistic clinical 
benefit for patients receiving combination regimens with immunotherapy.43,44 It has been 
demonstrated that the use of relatively low doses of external-beam radiation, insufficient to 
kill tumors, induces immunogenic modulation, thereby altering those tumor cells to render 
them more susceptible to T cell–mediated lysis.36,45 These findings have translated into 
promising clinical benefits for patients with HNSCC who are receiving RT plus 
immunotherapy. Of importance, it has been shown specifically with an in vitro model of 
HNSCC that treatment with RT and cisplatin chemotherapy can lead to synergistic 
sensitivity to antigen-specific T-cell killing.46
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Previously untreated, locally advanced HNSCC
Previously untreated, locally advanced, HPV-positive oropharyngeal cancer: In addition 
to the classic risk factors of tobacco and alcohol, HPV type 16 now represents a primary 
cause of HNSCC in North America and Europe.47,48 HPV status and pack-years of tobacco 
exposure are the major determinants of survival among patients with HNSCC, followed by 
lymph node stage.49 Based on these 3 prognostic factors, patients with HNSCC can be 
classified into 3 risk groups having a low, intermediate, or high risk of death. This clinical 
risk classification has framed national clinical trial priorities in PULA HNSCC. Specifically, 
deintensification strategies currently are being tested in patients with low-risk, HPV-positive 
HNSCC whereas intensification strategies represent the major unmet need for individuals 
with high-risk HPV-negative and intermediate-risk HPV-positive disease.50–52
For patients with HPV-positive, PULA HNSCC, working group 1 (Fig. 1) identified 2 
priorities: 1) more targeted HPV-specific therapy taking advantage of unique non-self, viral 
TAs present within HPV-positive tumors; and 2) to determine the sequencing and optimal 
chemoradiotherapy (CRT) regimens that do not inhibit immunotherapeutic efficacy (Fig. 1). 
Currently, immunotherapeutic trials open or currently in development include eliminating 
systemic cytotoxic chemotherapy by combining intensity-modulated radiotherapy with 
cetuximab and the anti-CTLA-4 MoAb ipilimumab (ClinicalTrials.gov identifier 
NCT01935921), in which the overlap of ipilimumab exposure begins at week 5 of treatment 
with cetuximab and RT. In addition, patients with “intermediate-risk,” HPV-positive and 
“high-risk,” HPV-negative disease will be treated with concurrent, weekly CRT with 
cisplatin with an anti-PD-1 MoAb, a natural “add-on” strategy that currently is in 
development (Radiation Therapy Oncology Group [RTOG] Foundation trial 3504) and will 
open to enrollment in the near future.
First-generation “deintensification” clinical trials for patients with HPV-positive PULA 
disease enrolled patients with both good and intermediate risk, with the goal of reducing 
chemotherapy and/or RT doses (fields) (Eastern Cooperative Oncology Group [ECOG] 
1308, RTOG 1016). As clinical risk stratification evolves, second-generation 
deintensification trials are selecting only good-risk patients (HN002). New trials are needed 
for patients with intermediate-risk, worse-prognosis, HPV-positive disease. The proposed 
trial aims to harness novel systemic immunotherapy and use the unique viral antigens (the 
oncogenes E6 and E7) expressed in HPV-positive HNSCC to improve disease-free survival 
(DFS) as well as make an impact on the burden of uncommon, although lethal, distant 
metastatic disease for patients with intermediate-risk, HPV-positive PULA disease (those 
with T3/4 disease, those with N2c/N3 disease, > 10 pack-year smokers, and HPV-positive 
patients52. The proposed concept (Fig. 1) would compare anti-PD-1 plus cisplatin CRT with 
the combination of anti-PD-1/CRT plus HPV-specific E6/E7 vaccination. Several vaccines 
currently are available and have been tested in phase 1 trials for cervical and other HPV-
positive cancers, and include peptide plus adjuvant, DNA-based or Listerolysin O-based 
vectors. Collaboration between a cooperative group and 1 or 2 pharmaceutical company 
sponsors is likely to be necessary. A neoadjuvant (pre-CRT) phase of 1 to 2 doses of vaccine 
with or without an anti-PD-1 MoAb was strongly considered because the timing and 
sequence of HPV-specific T-cell expansion vis-a-vis cytotoxic CRT, which may inhibit 
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lymphocyte expansion, is undetermined. This approach, although more cumbersome, also 
would permit the correlation of dynamic tumor and peripheral immune biomarkers with 
clinical outcomes.
PULA HPV-negative HNSCC—Approximately 80% of HNSCC diagnoses worldwide 
remain secondary to environmental carcinogens, including tobacco and alcohol. Recent 
improvements in 5-year OS for the HNSCC population as a whole are largely attributable to 
the epidemic of good-risk, HPV-positive HNSCC, which involves younger and lower-risk 
populations.48 The OS for patients with high-risk, PULA, HPV-negative HNSCC has 
improved only marginally within the last 20 years due to the incorporation of concurrent 
cisplatin in curative-intent paradigms. The current standard for the nonsurgical management 
of patients with PULA, HPV-negative, HNSCC is concurrent cisplatin and CRT, which 
improved OS, DFS, and locoregional control compared with RT alone in the sentinel 
Intergroup 0126 trial, a trial that was populated before the HPV epidemic.53,54 Standards for 
the adjuvant management of patients with PULA, HPV-negative, HNSCC are determined by 
pathologic risk. Specifically, for patients who demonstrated ≥1 high-risk pathologic features, 
including a positive surgical margin or extracapsular lymph node extension, concurrent 
cisplatin and RT appeared to provide a clinical benefit compared with RT alone in the 
landmark phase 3 European Organisation for Research and Treatment of Cancer (EORTC) 
22931 and RTOG 9501 trials.55,56 Despite this advance, patients with high-risk, HPV-
negative disease have a 3-year DFS rate of only 30% to 50%.55–57 Although locoregional 
control and OS are improved with concurrent cisplatin and RT, a meta-analysis indicated 
disappointing local and distant failure rates of 50% and 15%, respectively, and an absolute 
survival benefit of only 6.5% compared with RT alone.58 Poor outcomes persist despite 
intensification with altered fractionation,59 multidrug induction,60 or EGFR-targeted 
MoAbs.61
For HPV-negative patients, new intensification approaches represent a major unmet clinical 
need. The PULA HPV-negative working group initially discussed 2 clinical trial paradigms 
for patients with high-risk disease: 1) the integration of immunotherapy into definitive 
cisplatin CRT; and 2) the integration of immunotherapy into trimodality therapy for high-
risk patients (Fig. 2). Ultimately, the recommended focus on the trimodality model 
capitalized on 3 opportunities. First, the accessibility of the tumor and TME for serial 
assessment. The natural anatomy of HNSCC presents specific accessibility of the primary 
tumor and TME for serial biopsy. In the proposed trial, the incorporation of primary surgery 
permits a “window of opportunity” for exposure to a specific immunotherapy between 
diagnostic biopsy and planned surgery, thereby facilitating pharmacodynamic evaluation of 
the tumor and TME responses in paired specimens. The second opportunity is the 
integration of immunotherapy with RT (Figure 3). Ionizing RT induces adaptive immune 
responses via 3 broad mechanisms that could be synergistic with immunotherapy, including 
release of TAs for processing and presentation, upregulation of stimulatory chemokines 
within the TME, and increased tumoral expression of TA and MHC.62 The third opportunity 
is the integration of immunotherapy with cisplatin. Although cytotoxic chemotherapy is 
conventionally viewed as immunosuppressive, cisplatin also demonstrates stimulatory 
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effects, including upregulation of MHC, recruitment and proliferation of effector cells, 
enhanced cytolytic activity of effector cells, and downregulation of MDSCs and Treg cells.40
The immune checkpoint inhibitors, antagonizing the CTLA-4 or PD-1 pathways, were 
considered to be of greatest priority for development in the HPV-negative PULA population. 
First, environmentally induced HNSCC demonstrates a high mutational burden.63,64 
Mutational load, as well as the presence of highly immunogenic neoantigens, has been 
correlated with response to immune checkpoint inhibitors in other solid tumors.65,66 Second, 
RT dynamically upregulates PD-L1 on both tumor and MDSCs, thereby reducing the 
adaptive response and theoretically facilitating future disease recurrence. In 2 syngeneic 
preclinical models, concurrent PD-L1 blockade and RT were found to be synergistic in 
controlling tumor growth, and generated prolonged protective T-cell immunity, as 
demonstrated by subsequent abscopal effect.67
The central hypothesis of the proposed randomized phase 2 trial considers whether adding 
immunotherapy to CRT with adjuvant cisplatin increases the DFS in patients with high-risk, 
resected, PULA, HPV-negative HNSCC. In this trial design, the window of monotherapeutic 
exposure before definitive surgery creates a unique opportunity with which to study placebo-
controlled, pretreatment and posttreatment tumor and blood specimens to isolate immune 
mechanisms, and to correlate baseline and pharmacodynamic biomarkers with 2-year DFS. 
We propose to evaluate baseline and changes in immune-inflammatory biomarkers in both 
tumor and the TME, and to correlate these biomarkers with the 2-year DFS. Markers will 
include immunohistochemistry (IHC) or immunofluorescence (IF) for CD3, CD8, CD45RO, 
CD4/forkhead box P3 (FOXP3), PD-L1, and Ki-67; flow cytometry for tumor-infiltrating 
lymphocytes and MDSC subsets; T-cell activation panel and memory subsets; changes in T-
cell receptor (TCR) clonality; and whole exome sequencing for peptide-encoding tumor 
neoantigens.
Immunotherapy Trial Biomarkers and Unique HNSCC Patient Specimen Considerations
From tumor samples, IHC/IF detection of immune markers provide a measure of baseline 
immune cell infiltration, phenotype, localization, and “inflammation,” sometimes referred to 
as an “immunoscore” because this has been shown to have prognostic and predictive 
capacity for immunotherapy in other diseases, including colorectal cancer.68–71 These 
markers include CD3, CD8, CD45RO, CD4/FOXP3, and perhaps PDL-1 (on tumors vs 
myeloid cells). The biomarkers working group recommended combining these basic stains 
for infiltrate with the specific targets in a proposed trial (PD-1, CTLA-4, OX-40, TIM-3, 
LAG-3, CD40, etc). Multiplexed IF makes testing multiple parameters more feasible.72
From fresh frozen tissue, the following genomic or signaling assays were recommended 
(Table 3): 1) RNA analysis to determine the IFN-γ gene signature; 2) PD-L1 and PD-L2 
IHC staining on tumor and infiltration myeloid inflammatory cells; 3) RNA sequencing (to 
include the inhibitory/costimulation/exhaustion molecules targeted); 4) TCR diversity (as a 
measure of TCR skewing and clonality of the infiltrated T-cell response); and 5) any trial-
specific pathways (eg, phospho-SMAD in the setting of a transforming growth factor β 
[TGF-β] inhibitor study proposed at the CTPM).
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The above assessments would be performed on all biopsies taken, including the “window” 
(neoadjuvant) trials taking advantage of paired pretreatment and posttreatment tumor 
specimens in the HPV-negative and the HPV-positive PULA trials. A new biopsy would be 
needed for the R/M study (not on primary tumor banked earlier). Some technologies can use 
formalin-fixed, paraffin-embedded tissue, which is more easily obtained.
From peripheral blood samples (ie, ficoll-gradient separated peripheral blood mononuclear 
cells [PBMCs]), flow cytometry should accomplish the following: relative quantification of 
circulating suppressive MDSCs and Treg cells; T-cell activation panels (eg, inducible 
costimulator in CTLA-4 trials and CD69 for general activation); lymphocyte memory 
subsets (CD45RO, CCR7 central trafficking); NK cells; and PD-1, CTLA-4, and/or any trial 
design-related costimulatory/coinhibitory molecules. Specific intracellular molecules (TGF-
β: phospho-STAT) also would be measured. To the best of our knowledge, ECOG/American 
College of Radiology Imaging Network and NRG Oncology are not currently collecting and 
processing fresh PBMCs for functional and phenotypic studies, and processes, 
infrastructure, and funding support would need to be developed for real-time shipping, 
processing, and storage to take advantage of the great opportunities in different 
immunotherapeutic strategies being used and to maximize the predictive and prognostic as 
well as mechanism of action biomarker analyses.
Antigen-specific cytokine flow cytometry is possible using MHC: peptide multimers or non-
human leukocyte antigen-restricted overlapping peptide pools: for HPV-positive tumors, E6 
and E7 peptide pools (including testing for surface CD4 and CD8) and polyfunctional 
intracellular cytokines and effector molecules (IFN-γ, TNF-α, interleukin 2, and 
granzymes). For non-HPV tumors, shared tumor antigen peptide pools can be pursued (eg, 
p53, survivin) with surface CD4 and CD8, polyfunctional intracellular cytokines, and 
effector molecules. Control antigen peptide pools can be used to document and monitor 
memory recall responses. Additional cellular blood assays also were considered, including 
genomic single-nucleotide polymorphism analysis for possible predictive genomic 
biomarkers from PBMC germline DNA. Similarly, transcriptional signatures have been 
identified from peripheral blood messenger RNA that may be unbiased and hypothesis-
generating.
From serum, recommended assays include multiplex cytokine analysis (for a comparison of 
agents only) and inflammatory molecules (especially for cytokines) as potential mediators of 
toxicity (baseline interleukin 17 and CTLA-4 toxicity). Currently, 30 to 60 different analytes 
are tested in each small sample.
Imaging biomarkers are an important correlate in novel prospective trials but this field was 
believed to be underdeveloped as a whole in immunotherapy, given several factors. These 
include occasional “delayed” or atypical/ mixed responses, which are reflected in immune 
response Response Evaluation Criteria In Solid Tumors (RECIST) for R/M disease.73 For 
the short term, anti-PD-1 “window” neoadjuvant studies, [18F]fludeoxyglucose-positron 
emission tomography/computed tomography before and after 4-week induction may be a 
predictor of early response via standardized uptake value measurements, because anatomic 
shrinkage may not be observed in the short term. However, infiltrating immune cells may be 
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metabolically active, confounding interpretation of increased [18F]fludeoxyglucose avidity 
in the TME. The imaging biomarker experts noted that there is no current technology for the 
assessment of immune activity and infiltration via imaging, which represents a major unmet 
clinical need.
Potential pitfalls and additional considerations exist in these immune biomarker 
assessments. For example, there are unanswered technical questions regarding the feasibility 
of tumor analysis. For blood, given some limitations in volumes and yields, prioritization is 
needed for the different assays. It is assumed that absolute lymphocyte counts, which are a 
candidate biomarker for some checkpoint blockade therapies (particularly CTLA-4), are 
serially obtained before/during/after in clinical laboratories. Last, stool samples and oral 
swabs could be considered for future microbiome studies.
Conclusions
Cancer immunology is a rapidly evolving field, and only recently have we begun to 
understand the complex interaction between cancer and the host immune system. Tumor 
cells demonstrate several methods with which to exploit the immune system to help promote 
angiogenesis, derive pro-survival and proliferative signals, and induce metastasis and tumor 
progression. At the same time, cancers are able to cloak themselves from the immune 
system by self-modification and by immunosuppression of the host. Recent results from 
clinical trials provide evidence for effective anticancer immunotherapies. Because of the 
manifold tumor evasion strategies and hence different response rates for treatments, 
combination therapies will be helpful in developing cancer treatments.
The HNSCC Immunotherapy CTPM was designed to harness these insights and to generate 
a better under-standing of several promising immunotherapeutic agents that currently are in 
clinical use as well as others currently in development. Four clinical trial concepts emerged 
during this important and productive meeting. Great enthusiasm and collaborative effort will 
lead to the “hand-off” of these concepts to the head and neck committees of ECOG/
American College of Radiology Imaging Network and NRG Oncology for submission and 
review by NCI Cancer Therapy Evaluation Program and the Head and Neck Steering 
committee processes. Success will likely depend on the development of industry 
collaborations and support. The integration of industry into the open, educational portion of 
the meeting was intended to facilitate and enhance these interactions and relationships. 
Given the unique features of HNSCC, including tumor accessibility for serial biopsies and 
the balance between carcinogen and virally induced cancer subsets, these trials should 
provide important information for the field of immunotherapy as a whole.
Acknowledgments
FUNDING SUPPORT
Supported by the National Cancer Institute (NCI) Coordinating Center for Clinical Trials and developed under the 
leadership of the NCI Head & Neck Steering Committee.
This meeting was supported by the National Cancer Institute Coordinating Center for Clinical Trials and was 
developed under the leadership of the National Cancer Institute Head & Neck Steering Committee. We 
acknowledge the contributions of all of the working group participants, listed here: Group 1-Best Agent(s) and Trial 
Bauman et al. Page 12
Cancer. Author manuscript; available in PMC 2017 November 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Design in HPV (+) PULA Disease: Bryan Bell, Anthony Cmelak, Dimitrios Colevas, Adam Dicker, Avraham 
Eisbruch, Young-Jun Kim, Loren Mell, Harry Quon, Ralph Weichselbaum, Gregory Wolf, and Edward Zhang. 
Group 2-Best Agent(s) and Trial Designs in HPV (−) PULA Disease: Walter Lee, Mitchel Machtay, Judith Manola, 
Renato Martins, Michael Spiotto, Erich Sturgis, John Sunwoo, Ravindra Uppaluri, and Carter van Waes. Group 3-
Best Agent(s) and Trial Design in Recurrent/Metastatic Disease: Laura Chow, Christine Chung, Marka Crittenden, 
Antonio Jimeno, Holbrook Kohrt, John Lee, Brian Nussenbaum, Tanguy Seiwert, Andrew Sikora, Jeremy Taylor, 
and Stuart Wong. Group 4-Monitoring for Efficacy in Immunotherapeutic Trials-Specimen Analyses, Imaging, 
Correlative Immune Monitoring: Jorge Carrasquillo, Francesco Marincola, Jeffrey Moyer, Sara Pai, Elad Sharon, 
James Stapleton, Howard Streicher, Rathan Subramaniam, and Xiao-Jing Wang.
CONFLICT OF INTEREST DISCLOSURES
Julie E. Bauman has acted as a paid scientific consultant for Lilly, Merck, Incyte, and EMD-Serono and has 
received a clinical trial research grant from Merck for work performed outside of the current study. Ezra Cohen has 
received fees from Bristol-Myers Squibb, Pfizer, and AstraZeneca for work performed outside of the current study. 
Robert L. Ferris has received grants from and acted as a paid member of the Advisory Board for AstraZeneca/
MedImmune, Bristol-Myers Squibb, and Merck; acted as a paid member of the Advisory Board for Lilly and 
Pfizer; and has received a grant from VentiRx Pharmaceuticals for work performed outside of the current study. 
Barbara A. Burtness has received a grant and personal fees from Merck, a grant from Advaxis, and personal fees 
from AstraZeneca and Amgen for work performed outside of the current study. Mary L. Disis has received grants 
from VentiRx, EMD-Serono, Celgene, Janssen, and Seattle Genetics for work performed outside of the current 
study, and is a stockholder in VentiRx and Epithany. Bernard A. Fox has received grants from Bristol-Myers Squibb 
and AstraZeneca/Medimmune for work performed as part of the current study. Dr. Fox is also founder and owner of 
UbiVac; has received personal fees from Argos, Dendreon, 3M, and Ventana/ Roche; has received nonfinancial 
support from Aduro and Definiens; has received grants and personal fees from Janssen/Johnson & Johnson; has 
received personal fees and nonfinancial support from PerkinElmer; and has received a grant from Viralytics for 
work performed outside of the current study. In addition, Dr. Fox has a patent (US 20140112977 A1) licensed to 
UbiVac. Thomas F. Gajewski has received a grant from and acted as a paid member of the Advisory Board for 
Merck; acted as a paid member of the Advisory Board for Incyte, Roche, Bayer, AbbVie, Forma, and Jounce; has 
received grants from Bristol-Myers Squibb, Seattle Genetics, Genentech/Roche, and Ono; and has patents from 
Evelo and Aduro. Maura L. Gillison has received a clinical trial contract from Bristol-Myers Squibb to Ohio State 
University and personal fees from Bristol-Myers Squibb for consulting and lectures for work performed as part of 
the current study and has received travel costs from Merck, Lilly, Amgen, AstraZeneca, Bristol-Myers Squibb, and 
Celgene and a clinical trial contract to Ohio State University from AstraZeneca, Merck, and Bristol-Myers Squibb 
for work performed outside of the current study. David Raben has received personal fees from AstraZeneca and 
Merck for work performed outside of the current study. Scott E. Strome has stock in, is a cofounder of, has received 
research support from, and acted as a paid consultant for Gliknik; has received research support from Pfizer; has 
received payment from the Mayo Clinic College of Medicine for IP licensed to third parties regarding the clinical 
application of B7-H1; and has had 3 patents issued and licensed and receives royalties from them through the Mayo 
Clinic.
References
1. Pardoll D. Cancer and the immune system: basic concepts and targets for intervention. Semin Oncol. 
2015; 42:523–538. [PubMed: 26320058] 
2. Ferris RL. Immunology and immunotherapy of head and neck cancer. J Clin Oncol. 2015; 33:3293–
3304. [PubMed: 26351330] 
3. Ferris RL, Jaffee EM, Ferrone S. Tumor antigen-targeted, monoclonal antibody-based 
immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol. 2010; 
28:4390–4399. [PubMed: 20697078] 
4. Yewale C, Baradia D, Vhora I, Patil S, Misra A. Epidermal growth factor receptor targeting in 
cancer: a review of trends and strategies. Biomaterials. 2013; 34:8690–8707. [PubMed: 23953842] 
5. Rubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head 
and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998; 90:824–832. 
[PubMed: 9625170] 
6. Ramsay AG. Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity. 
Br J Haematol. 2013; 162:313–325. [PubMed: 23691926] 
7. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. 
Science. 1996; 271:1734–1736. [PubMed: 8596936] 
8. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with 
metastatic melanoma. N Engl J Med. 2010; 363:711–723. [PubMed: 20525992] 
Bauman et al. Page 13
Cancer. Author manuscript; available in PMC 2017 November 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
9. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in 
melanoma. N Engl J Med. 2013; 36:134–144.
10. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-
tumor immunity. Curr Opin Immunol. 2012; 2:207–212.
11. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 
antibody in cancer. N Engl J Med. 2012; 366:2443–2454. [PubMed: 22658127] 
12. Callahan MK, Wolchok JD. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer 
immunotherapy. J Leukoc Biol. 2013; 94:41–53. [PubMed: 23667165] 
13. Ferris R, Blumenschein G Jr, Fayette J, et al. Further evaluation of nivolumab versus investigator’s 
choice systemic therapy for recurrent or metastatic squamous cell carcinoma of the head and neck 
[abstract]. J Clin Oncol. 2016; 34 suppl; abstr 6009. 
14. Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for 
treatment of recurrent or metastatic squamous cell carcinoma of the head and neck 
(KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016; 17:956–965. 
[PubMed: 27247226] 
15. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a 
potential mechanism of immune evasion. Nat Med. 2002; 8:793–800. [PubMed: 12091876] 
16. Concha-Benavente F, Srivastava RM, Trivedi S, et al. Identification of the cell-intrinsic and 
extrinsic pathways downstream of EGFR and IFNγ that induce PD-L1 expression in head and 
neck cancer. Cancer Res. 2016; 76:1031–1043. [PubMed: 26676749] 
17. Badoual C, Hans S, Merillon N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable 
prognostic biomarker in HPV-associated head and neck cancer. Cancer Res. 2013; 73:128–138. 
[PubMed: 23135914] 
18. Concha-Benavente F, Srivastava R, Ferrone S, Ferris RL. Immunological and clinical significance 
of HLA class I antigen processing machinery component defects in malignant cells. Oral Oncol. 
2016; 58:52–58. [PubMed: 27264839] 
19. Strome SE, Dong H, Tamura H, et al. B7-H1 blockade augments adoptive T-cell immunotherapy 
for squamous cell carcinoma. Cancer Res. 2003; 63:6501–6505. [PubMed: 14559843] 
20. Jie HB, Gildener-Leapman N, Li J, et al. Intratumoral regulatory T cells upregulate 
immunosuppressive molecules in head and neck cancer patients. Br J Cancer. 2013; 109:2629–
2635. [PubMed: 24169351] 
21. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma 
of the head and neck [published online ahead of print October 8, 2016]. N Engl J Med. 
22. Melero I, Hirschhorn-Cymerman D, Morales-Kastresana A, Sanmamed MF, Wolchok JD. Agonist 
antibodies to TNFR molecules that costimulate T and NK cells. Clin Cancer Res. 2013; 19:1044–
1053. [PubMed: 23460535] 
23. Stephenson RM, Lim CM, Matthews M, Dietsch G, Hershberg R, Ferris RL. TLR8 stimulation 
enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic 
cell cross-priming of EGFR-specific CD8 + T cells. Cancer Immunol Immunother. 2013; 62:1347–
1357. [PubMed: 23685782] 
24. Fakhry C, Zhang Q, Nguyen-Tan PF, et al. Human papillomavirus and overall survival after 
progression of oropharyngeal squamous cell carcinoma. J Clin Oncol. 2014; 32:3365–3373. 
[PubMed: 24958820] 
25. Hong WK, Schaefer S, Issell B, et al. A prospective randomized trial of methotrexate versus 
cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck. Cancer. 
1983; 52:206–210. [PubMed: 6190545] 
26. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil 
and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the 
head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992; 10:1245–1251. [PubMed: 
1634913] 
27. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and 
neck cancer. N Engl J Med. 2008; 359:1116–1127. [PubMed: 18784101] 
Bauman et al. Page 14
Cancer. Author manuscript; available in PMC 2017 November 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
28. Vermorken JB, Herbst RS, Leon X, Amellal N, Baselga J. Overview of the efficacy of cetuximab in 
recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who 
previously failed platinum-based therapies. Cancer. 2008; 112:2710–2719. [PubMed: 18481809] 
29. Levin D, Golding B, Strome SE, Sauna ZE. Fc fusion as a platform technology: potential for 
modulating immunogenicity. Trends Biotechnol. 2015; 33:27–34. [PubMed: 25488117] 
30. Zandberg DP, Strome SE. The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the 
head and neck. Oral Oncol. 2014; 50:627–632. [PubMed: 24819861] 
31. Lin W, Voskens CJ, Zhang X, et al. Fc dependent expression of CD137 on human NK cells: 
insights into “agonistic” effects of anti-CD137 monoclonal antibodies. Blood. 2008; 112:699–707. 
[PubMed: 18519814] 
32. Srivastava RM, Trivedi S, Concha-Benavente F, et al. CD137 stimulation enhances cetuximab 
induced natural killer (NK): dendritic cell (DC) priming of anti-tumor T cell immunity in head and 
neck cancer patients [published online ahead of print August 5, 2016]. Clin Cancer Res. 
33. Kohrt HE, Houot R, Weiskopf K, et al. Stimulation of natural killer cells with a CD137-specific 
antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest. 
2012; 122:1066–1075. [PubMed: 22326955] 
34. Kohrt HE, Colevas AD, Houot R, et al. Targeting CD137 enhances the efficacy of cetuximab. J 
Clin Invest. 2014; 124:2668–2682. [PubMed: 24837434] 
35. Srivastava RM, Lee SC, Andrade Filho PA, et al. Cetuximab-activated natural killer and dendritic 
cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer 
patients. Clin Cancer Res. 2013; 19:1858–1872. [PubMed: 23444227] 
36. Hodge JW, Ardiani A, Farsaci B, Kwilas AR, Gameiro SR. The tipping point for combination 
therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. 
Semin Oncol. 2012; 39:323–339. [PubMed: 22595055] 
37. Kepp O, Senovilla L, Vitale I, et al. Consensus guidelines for the detection of immunogenic cell 
death. Oncoimmunology. 2014; 3:e955691. [PubMed: 25941621] 
38. Kepp O, Galluzzi L, Martins I, et al. Molecular determinants of immunogenic cell death elicited by 
anticancer chemotherapy. Cancer Metastasis Rev. 2011; 30:61–69. [PubMed: 21249425] 
39. Hodge JW, Kwilas A, Ardiani A, Gameiro SR. Attacking malignant cells that survive therapy: 
exploiting immunogenic modulation. Oncoimmunology. 2013; 2:e26937. [PubMed: 24498561] 
40. de Biasi AR, Villena-Vargas J, Adusumilli PS. Cisplatin-induced antitumor immunomodulation: a 
review of preclinical and clinical evidence. Clin Cancer Res. 2014; 20:5384–5391. [PubMed: 
25204552] 
41. Hodge JW, Garnett CT, Farsaci B, et al. Chemotherapy-induced immunogenic modulation of tumor 
cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int 
J Cancer. 2013; 133:624–636. [PubMed: 23364915] 
42. Gameiro SR, Caballero JA, Higgins JP, Apelian D, Hodge JW. Exploitation of differential 
homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of 
vaccine-mediated antitumor responses. Cancer Immunol Immunother. 2011; 60:1227–1242. 
[PubMed: 21544650] 
43. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J 
Natl Cancer Inst. 2013; 105:256–265. [PubMed: 23291374] 
44. Kwilas AR, Donahue RN, Bernstein MB, Hodge JW. In the field: exploiting the untapped potential 
of immunogenic modulation by radiation in combination with immunotherapy for the treatment of 
cancer. Front Oncol. 2012; 2:104. [PubMed: 22973551] 
45. Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW. Radiation-induced 
immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, 
resulting in enhanced T-cell killing. Oncotarget. 2014; 5:403–416. [PubMed: 24480782] 
46. Gelbard A, Garnett CT, Abrams SI, et al. Combination chemotherapy and radiation of human 
squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Clin Cancer Res. 
2006; 12:1897–1905. [PubMed: 16551875] 
47. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human 
papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin 
Oncol. 2008; 26:612–619. [PubMed: 18235120] 
Bauman et al. Page 15
Cancer. Author manuscript; available in PMC 2017 November 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
48. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal 
cancer incidence in the United States. J Clin Oncol. 2011; 29:4294–4301. [PubMed: 21969503] 
49. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with 
oropharyngeal cancer. N Engl J Med. 2010; 363:24–35. [PubMed: 20530316] 
50. O’Sullivan B, Huang SH, Perez-Ordonez B, et al. Outcomes of HPV-related oropharyngeal cancer 
patients treated by radiotherapy alone using altered fractionation. Radiother Oncol. 2012; 103:49–
56. [PubMed: 22410204] 
51. Marur S, Li S, Cmelak A, et al. E 1308: a phase II trial of induction chemotherapy followed by 
cetuximab with low dose versus standard dose IMRT in patients with human papilloma virus-
associated resectable squamous cell carcinoma of the oropharynx [abstract]. J Clin Oncol. 2013; 
31 suppl; abstr 6005. 
52. O’Sullivan B, Huang SH, Siu LL, et al. Deintensification candidate subgroups in human 
papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J 
Clin Oncol. 2013; 31 suppl; abstr 6005. 
53. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet. 2008; 371:1695–
1709. [PubMed: 18486742] 
54. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation 
therapy and 2 schedules of concurrent chemoradiotherapy in patients with unresectable squamous 
cell head and neck cancer. J Clin Oncol. 2003; 21:92–98. [PubMed: 12506176] 
55. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and 
chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004; 
350:1937–1344. [PubMed: 15128893] 
56. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant 
chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004; 350:1945–1952. 
[PubMed: 15128894] 
57. Harari PM, Harris J, Kies MS, et al. Postoperative chemoradiotherapy and cetuximab for high-risk 
squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. 
J Clin Oncol. 2014; 32:2486–2495. [PubMed: 25002723] 
58. Pignon JP, le Maitre A, Maillard E, Bourhis J. MACH-NC Collaborative Group. Meta-analysis of 
chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 
17,346 patients. Radiother Oncol. 2009; 92:4–14. [PubMed: 19446902] 
59. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent 
chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998; 338:1798–1804. 
[PubMed: 9632446] 
60. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in 
head and neck cancer. N Engl J Med. 2007; 357:1705–1715. [PubMed: 17960013] 
61. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of 
the head and neck. N Engl J Med. 2006; 354:567–578. [PubMed: 16467544] 
62. Hodge JW, Guha C, Neefjes J, Gulley JL. Synergizing radiation therapy and immunotherapy for 
curing incurable cancers. Opportunities and challenges. Oncology (Williston Park). 2008; 
22:1064–1070. discussion 1075, 1080–1081, 1084. [PubMed: 18777956] 
63. Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck 
squamous cell carcinomas. Nature. 2015; 517:576–582. [PubMed: 25631445] 
64. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous 
cell carcinoma. Science. 2011; 333:1157–1160. [PubMed: 21798893] 
65. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade 
in melanoma. N Engl J Med. 2014; 371:2189–2199. [PubMed: 25409260] 
66. Gubin MM, Zhang X, Schuster H, et al. Checkpoint blockade cancer immunotherapy targets 
tumour-specific mutant antigens. Nature. 2014; 515:577–581. [PubMed: 25428507] 
67. Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote 
antitumor immunity in mice. J Clin Invest. 2014; 124:687–695. [PubMed: 24382348] 
68. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within 
human colorectal tumors predict clinical outcome. Science. 2006; 313:1960–1964. [PubMed: 
17008531] 
Bauman et al. Page 16
Cancer. Author manuscript; available in PMC 2017 November 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
69. Seiwert T. Antitumor activity and safety of pembrolizumab in patients (pts) with advanced 
squamous cell carcinoma of the head and neck (SCCHN): preliminary results from 
KEYNOTE-012 expansion cohort [abstract]. J Clin Oncol. 2015; 33 suppl; abstr LBA6008. 
70. Gajewski TF. The next hurdle in cancer immunotherapy: overcoming the non-T-cell-inflamed 
tumor microenvironment. J Clin Oncol. 2015; 33 suppl; abstr LBA6008. 
71. Fox BA, Schendel DJ, Butterfield LH, et al. Defining the critical hurdles in cancer immunotherapy. 
J Transl Med. 2011; 9:214. [PubMed: 22168571] 
72. Stack EC, Foukas PG, Lee PP. Multiplexed tissue biomarker imaging. J Immunother Cancer. 2016; 
4:9. [PubMed: 26885371] 
73. Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in 
solid tumors: immune-related response criteria. Clin Cancer Res. 2009; 15:7412–7420. [PubMed: 
19934295] 
Bauman et al. Page 17
Cancer. Author manuscript; available in PMC 2017 November 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Working Group 1. Window immunotherapy biomarker study followed by definitive 
chemoradiotherapy (CRT) plus human papillomavirus (HPV) vaccine, anti-programmed 
death 1 (PD-1)/PD-ligand 1 axis (PD1/PL1) monoclonal antibody (mAb), or both in patients 
with T4 or N3, HPV-positive (+) oropharynx cancer. CT indicates computed tomography; 
DDP, cisplatin; Gy, grays; HNSCC, head and neck squamous cell carcinoma; PD-L1, 
programmed death-ligand 1; PULA, previously untreated, locally advanced; TME, tumor 
microenvironment.
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Figure 2. 
Working Group 2. Randomized, phase 2 study of adjuvant cisplatin and radiotherapy with or 
without antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody (mAb) in patients 
with high-risk, human papillomavirus (HPV)-negative (−) head and neck cancer with 
window correlatives. CRT indicates chemoradiotherapy; CT, computed tomography; DFS, 
disease-free survival; ECOG, Eastern Cooperative Oncology Group; IMRT, intensity-
modulated radiotherapy; PD1/L1, programmed death 1 (PD-1)/PD-ligand 1 axis; TME, 
tumor microenvironment.
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Figure 3. 
Working Group 3. A randomized phase 2 study of stereotactic body radiosurgery (SBRT) 
plus antiprogrammed death 1 (PD-1)/PD-ligand 1 axis (PD1/L1) monoclonal antibody 
(mAb) versus antiprogrammed death-ligand 1 (PD1/L1) mAb alone for oligometastatic head 
and neck cancer. Gy indicates grays; HNSCC, head and neck squamous cell carcinoma; IV, 
intravenously; q, every; TME, tumor microenvironment.
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TABLE 1
Potential Therapeutic Targets in Head & Neck Squamous Cell Carcinoma (HNSCC)
Drug (Company) Target IgG Class HNSCC DevelopmentStage
Proposed Mechanism of
Action
Tumor antigen-targeted MoAbs
Cetuximab (Bristol-Myers Squibb, Eli Lilly) EGFR antagonist IgG1 Phase 3/4 Tumor growth inhibition, 
cellular immunity
Panitumumab (Amgen) EGFR antagonist IgG2 Phase 2/3 Tumor growth inhibition
AV-203 (Aveo) HER3 antagonist IgG1 Phase I (monotherapy; 
cetuximab combination)
Tumor growth inhibition
Cixutumumab (Eli Lilly) IGFR antagonist IgG1 Phase 0–2 (neoadjuvant 
monotherapy; cetuximab 
combination)
Tumor growth inhibition
Cytokine -targeted MoAbs
Bevacizumab (Genentech) VEGF neutralizing Ab IgG1 Phase 3 (platinum 
chemotherapy+/−)
Inhibition of angiogenesis, 
impairment of VEGF-
induced 
immunosuppression
Ficlatuzumab (Aveo) HGF neutralizing Ab IgG1 Phase 1 (cetuximab 
combination; cisplatin-
RT combination)
Tumor growth inhibition
TNF receptor-targeted MoAbs
MEDI0562 (AstraZeneca/Medimmune) OX40 agonist IgG2 Phase 1b Stimulation of cellular 
immunity
Urelumab (Bristol-Myers Squibb) CD137 agonist IgG4 Phase 1 Stimulation of cellular 
immunity
PF-05082566 (Pfizer) CD137 agonist IgG2 Phase 1 Stimulation of cellular 
immunity
Immune checkpoint targeted MoAbs
Ipilimumab (Bristol-Myers Squibb) CTLA-4 IgG1 Phase 1 (cetuximab-RT 
combination)
Blockade/depletion of Treg, 
enhancement of CTL
Tremelimumab ( AstraZeneca/Medimmune) CTLA-4 IgG2 Phase 1 Blockade/depletion of Treg, 
enhancement of CTL 
activity
MEDI4736 (AstraZeneca/Medimmune) PD-L1 IgG1 Phase 2 Enhancement of CTL 
activity
Pembrolizumab (MK-3475; Merck) PD-1 IgG4 Phase 1 Enhancement of CTL 
activity
Nivolumab (Bristol-Myers Squibb) PD-1 IgG4 Phase 3 Enhancement of CTL 
activity
Abbreviations: CTL, cytotoxic T-lymphocyte; CTLA-4, cytotoxic T-lymphocyte antigen 4; EGFR, epidermal growth factor receptor; HER3, human 
epidermal growth factor receptor 3; HGF, hepatocyte growth factor; HNSCC, head and neck squamous cell carcinoma; IGFR, insulin-like growth 
factor receptor; IgG, immunoglobulin G; MoAb, monoclonal antibodies; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 
1; RT, radiotherapy; Treg, regulatory T cell; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.
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TABLE 2
Immunotherapeutic Agents
Drug Mechanism
Enhancing ADCC
IL-12 (NCI) Cytokine agonist of NK cell activation
IL-15 (NCI) Cytokine agonist of NK cell activation
VTX-2337 TLR 8 agonist; enhanced DC activation andh IL-12 secretion
Lirilumab (Bristol-Myers Squibb) Anti-KIR MoAb
1-7F9 (Innate) Anti-KIR MoAb
Targeting immunosuppressive cytokines
Siltuximab Anti-IL-6 MoAb
CAT-192 Anti-TGF-β MoAb
T-cell costimulatory agonists
CP-870,893 (Pfizer) CD40 agonist MoAb
OX40 MoAb (AgonOx; Providence Health) OX40 agonist MoAb
Urelumab (Bristol-Myers Squibb) CD137 agonist MoAb
PF-05082566 (Pfizer) CD137 agonist MoAb
IMP321 (Immutep) Recombinant soluble dimeric LAG-3
T-cell immune checkpoint inhibitors
Ipilimumab (Bristol-Myers Squibb) Anti-CTLA-4 MoAb
Tremelimumab (AstraZeneca/Medimmune) Anti-CTLA-4 MoAb
Nivolumab (Bristol-Myers Squibb) Anti-PD-1 MoAb
Pembrolizumab (Merck) Anti-PD-1 MoAb
Durvalumab (MEDI-4736 (AstraZeneca/Medimmune) Anti-PD-L1 MoAb
MPDL3280A (Genentech) Anti-PD-L1 MoAb
MSB0010718C (EMD-Serono) Anti-PD-L1 MoAb
AUNP12 (peptide) (Pierre Fabre/Aurigene) Anti-PD-L1 peptide
BMS-986016 (Bristol-Myers Squibb) Anti-LAG-3 MoAb
INCB024360 (Incyte) Orally available inhibitor
of indoleamine 2,3-dioxygenase (IDO1)
Abbreviations: ADCC, antibody-dependent cell-mediated cytotoxicity; CTLA-4, cytotoxic T-lymphocyte antigen 4; DC, dendritic cells; IL, 
interleukin; KIR, killer inhibitor receptor; LAG-3, lymphocyte-activation protein 3; MoAb, monoclonal antibody; NCI, National Cancer Institute; 
NK, natural killer; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; TGF-β, tumor growth factor-β; TLR, toll-like 
receptor.
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TABLE 3
Correlative Biomarkers for Cancer Immunotherapy
Tumor PBMC Serum Imaging Future
Infiltrate: CD3, CD8, CD45RO, 
CD4/FOXP3, PD-L1; 
frequency, location IHC, IF
Suppressors: Treg, MDSC Multiplexed circulating 
cytokines, chemokines, 
growth factors
FDG-
PET/CT 
before and 
after 4-wk 
induction
Stool/oral swabs for 
microbiome
Major checkpoints/
costimulatory (PD-1, CTLA-4, 
TIM-3, LAG-3, OX-40, and 
CD40)
Effector activation (ICOS, 
CD69), effector/memory, 
cytotoxicity
Circulating antibodies Imaging immune response
NK cells NK cells
Ki-67 Trial-specific pathways
RNA Seq HPV-positive: virus peptide 
pools
TCR diversity HPV-negative: shared tumor 
antigen peptide pools
Trial-specific pathways ALC as SOC
Abbreviations: ALC, acetyl-l-carnitine; CT, computed tomography; CTLA-4, cytotoxic T-lymphocyte antigen 4; FDG-PET, [18F]fludeoxyglucose-
positron emission tomography; FOXP3, forkhead box P3; HPV, human papillomavirus; ICOS, inducible costimulator; IF, immunofluorescence; 
IHC, immunohistochemistry; LAG-3, lymphocyte-activation protein 3; MDSC, myeloid-derived suppressor cells; NK, natural killer; PBMC, 
peripheral blood mononuclear cells; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; SOC, standard of care; Treg, 
regulatory T cells; TCR, T-cell receptor; TIM-3, T-cell immunoglobulin 3.
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